Centessa Pharmaceuticals Stock Surpasses Analyst Target Price
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2026
0mins
Should l Buy CNTA?
Source: NASDAQ.COM
- Stock Performance: Centessa Pharmaceuticals shares traded at $39.72, surpassing the average analyst 12-month target price of $39.64, indicating a positive market sentiment regarding the company's future performance.
- Analyst Reactions: When a stock reaches an analyst's target price, they typically either downgrade the valuation or raise the target, reflecting varying perspectives on the company's fundamental developments, which may influence investor decisions.
- Target Price Distribution: Among analysts covered by Zacks, the average target price for Centessa Pharmaceuticals is $39.64 with a standard deviation of $8.472, indicating significant divergence in analyst opinions, with the lowest target at $30.00 and the highest at $62.00.
- Investor Signal: As the stock price exceeds the average target, investors are prompted to reassess Centessa Pharmaceuticals' valuation, considering whether to hold or reduce their positions, reflecting differing expectations about the company's future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNTA
Wall Street analysts forecast CNTA stock price to fall
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.610
Low
27.00
Averages
38.75
High
62.00
Current: 39.610
Low
27.00
Averages
38.75
High
62.00
About CNTA
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Acquires Centessa Pharmaceuticals for Over $6 Billion
- Acquisition Amount and Market Reaction: Eli Lilly announced the acquisition of Centessa Pharmaceuticals at $38 per share, totaling over $6.3 billion, with a positive market response reflected in a 0.85% stock price increase, indicating investor confidence in the deal.
- Funding Sources and Financial Health: Although specific funding methods were not disclosed, Lilly's $7.2 billion cash reserves and over $42 billion in long-term debt, combined with annual revenues exceeding $65 billion, demonstrate its financial capacity to support the acquisition.
- Drug Development Potential: Centessa's lead drug candidate, cleminorexton, shows promising results in treating sleep disorders and is currently in phase 2a clinical trials, which could provide significant competitive advantages for Lilly if successful.
- Strategic Significance and Future Outlook: This acquisition is part of Lilly's ongoing growth strategy and may drive innovation in the neuroscience field, further solidifying its leadership position in the global pharmaceutical market.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) regarding its sale to Biogen Inc. for $41.00 per share in cash and two contingent value rights of $2.00 each, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The firm encourages Apellis shareholders to understand their legal rights and options, emphasizing free consultations to ensure that shareholder interests are protected in the transaction.
- Additional Company Investigations: Centessa Pharmaceuticals plc (NASDAQ:CNTA) is also under scrutiny for its sale to Eli Lilly for $38.00 per share plus a contingent value right of up to $9.00, with Halper Sadeh LLC investigating possible breaches of fiduciary duties.
- Legal Relief Measures: Halper Sadeh LLC represents investors globally, seeking increased consideration, additional disclosures, or other relief to advocate for the rights of affected shareholders.
See More
Sysco and McCormick Announce Major Acquisitions
- Sysco Acquisition Update: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across 700,000 restaurants, although it faces potential antitrust scrutiny that could complicate the deal.
- McCormick and Unilever Merger: McCormick announced a $44 billion merger with Unilever's food division, despite being valued at only $14 billion itself, indicating a strategic move to leverage scale and synergies, though past similar deals have often failed to deliver expected value.
- M&A Activity in Food Sector: The recent surge in mergers within the food industry highlights a market trend towards consolidation and economies of scale, yet historical data suggests that many large consumer brand mergers have not yielded positive outcomes, prompting investors to proceed with caution.
- Eli Lilly's Centessa Acquisition: Eli Lilly is acquiring Centessa Pharmaceuticals for $7.8 billion, focusing on expediting the market entry of a promising narcolepsy treatment, despite Centessa lacking commercial products, with success hinging on upcoming clinical trial results.
See More
Surge in M&A Activity in the Food Sector
- Sysco Acquisition Move: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across its network of 700,000 restaurants, thereby solidifying its leadership position in the U.S. food service distribution market.
- McCormick and Unilever Merger: McCormick announced a merger with Unilever's food division valued at $44 billion, despite McCormick's market cap of only $14 billion, indicating a strategy to leverage scale and resource integration for improved profitability, though it faces integration risks.
- Market Reactions and Risks: Analysts express caution regarding both Sysco and McCormick's transactions, particularly with Sysco taking on $21 billion in new debt, which could impact its financial stability, while the success of McCormick's merger strategy remains to be seen.
- Eli Lilly Acquires Centessa: Eli Lilly announced the acquisition of Centessa Pharmaceuticals for $7.8 billion, focusing on rare disease treatments; if FDA approval is secured, it could tap into a $5 billion market, reflecting strong demand and investment willingness in the pharmaceutical sector.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating companies like Apellis Pharmaceuticals, KORE Group Holdings, and Centessa Pharmaceuticals for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Apellis Transaction Details: Apellis Pharmaceuticals is being sold to Biogen Inc. for $41.00 per share in cash, along with a non-transferable right to receive two payments of $2.00 each, contingent on meeting specific global net sales thresholds, potentially affecting shareholder returns.
- KORE Transaction Situation: KORE Group Holdings is being sold for $9.25 per share to Searchlight Capital Partners and Abry Partners, prompting shareholders to consider the implications of this transaction on their rights and available legal options.
- Centessa Transaction Analysis: Centessa Pharmaceuticals is being sold for $38.00 per share in cash, plus a non-transferable right entitling holders to receive up to $9.00 upon achieving certain milestones, urging shareholders to understand their legal rights and options.
See More
Monteverde Law Firm Investigates Multiple Biotech Companies
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Kezar Life Sciences, Inc. and Aurinia Pharmaceuticals Inc., with Kezar shareholders expected to receive $6.955 per share in cash and a non-transferable contingent value right, aiming to protect shareholder interests and ensure transaction fairness.
- Centessa Transaction Details: In the deal between Centessa Pharmaceuticals plc and Eli Lilly, Centessa shareholders are anticipated to receive $38.00 per share in cash along with a contingent value right that could yield up to $9.00 based on certain milestones, demonstrating the company's commitment to shareholder value.
- Talkspace Shareholder Rights: In the transaction involving Talkspace, Inc. and Universal Health Services, Inc., Talkspace shareholders will receive $5.25 per share in cash, indicating the deal aims to provide direct cash returns to shareholders and enhance their confidence.
- Warner Bros. Transaction Progress: Warner Bros. Discovery, Inc. is set to receive $31.00 per share in cash and additional compensation based on elapsed time in its deal with Paramount Skydance Corporation, with a shareholder vote scheduled for April 23, 2026, reflecting the company's transparency and the importance of shareholder engagement in mergers.
See More
Eli Lilly Acquires Centessa Pharmaceuticals for Over $6 Billion
- Acquisition Amount and Market Reaction: Eli Lilly announced the acquisition of Centessa Pharmaceuticals at $38 per share, totaling over $6.3 billion, with a positive market response reflected in a 0.85% stock price increase, indicating investor confidence in the deal.
- Funding Sources and Financial Health: Although specific funding methods were not disclosed, Lilly's $7.2 billion cash reserves and over $42 billion in long-term debt, combined with annual revenues exceeding $65 billion, demonstrate its financial capacity to support the acquisition.
- Drug Development Potential: Centessa's lead drug candidate, cleminorexton, shows promising results in treating sleep disorders and is currently in phase 2a clinical trials, which could provide significant competitive advantages for Lilly if successful.
- Strategic Significance and Future Outlook: This acquisition is part of Lilly's ongoing growth strategy and may drive innovation in the neuroscience field, further solidifying its leadership position in the global pharmaceutical market.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) regarding its sale to Biogen Inc. for $41.00 per share in cash and two contingent value rights of $2.00 each, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The firm encourages Apellis shareholders to understand their legal rights and options, emphasizing free consultations to ensure that shareholder interests are protected in the transaction.
- Additional Company Investigations: Centessa Pharmaceuticals plc (NASDAQ:CNTA) is also under scrutiny for its sale to Eli Lilly for $38.00 per share plus a contingent value right of up to $9.00, with Halper Sadeh LLC investigating possible breaches of fiduciary duties.
- Legal Relief Measures: Halper Sadeh LLC represents investors globally, seeking increased consideration, additional disclosures, or other relief to advocate for the rights of affected shareholders.
See More
Sysco and McCormick Announce Major Acquisitions
- Sysco Acquisition Update: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across 700,000 restaurants, although it faces potential antitrust scrutiny that could complicate the deal.
- McCormick and Unilever Merger: McCormick announced a $44 billion merger with Unilever's food division, despite being valued at only $14 billion itself, indicating a strategic move to leverage scale and synergies, though past similar deals have often failed to deliver expected value.
- M&A Activity in Food Sector: The recent surge in mergers within the food industry highlights a market trend towards consolidation and economies of scale, yet historical data suggests that many large consumer brand mergers have not yielded positive outcomes, prompting investors to proceed with caution.
- Eli Lilly's Centessa Acquisition: Eli Lilly is acquiring Centessa Pharmaceuticals for $7.8 billion, focusing on expediting the market entry of a promising narcolepsy treatment, despite Centessa lacking commercial products, with success hinging on upcoming clinical trial results.
See More
Surge in M&A Activity in the Food Sector
- Sysco Acquisition Move: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across its network of 700,000 restaurants, thereby solidifying its leadership position in the U.S. food service distribution market.
- McCormick and Unilever Merger: McCormick announced a merger with Unilever's food division valued at $44 billion, despite McCormick's market cap of only $14 billion, indicating a strategy to leverage scale and resource integration for improved profitability, though it faces integration risks.
- Market Reactions and Risks: Analysts express caution regarding both Sysco and McCormick's transactions, particularly with Sysco taking on $21 billion in new debt, which could impact its financial stability, while the success of McCormick's merger strategy remains to be seen.
- Eli Lilly Acquires Centessa: Eli Lilly announced the acquisition of Centessa Pharmaceuticals for $7.8 billion, focusing on rare disease treatments; if FDA approval is secured, it could tap into a $5 billion market, reflecting strong demand and investment willingness in the pharmaceutical sector.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating companies like Apellis Pharmaceuticals, KORE Group Holdings, and Centessa Pharmaceuticals for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Apellis Transaction Details: Apellis Pharmaceuticals is being sold to Biogen Inc. for $41.00 per share in cash, along with a non-transferable right to receive two payments of $2.00 each, contingent on meeting specific global net sales thresholds, potentially affecting shareholder returns.
- KORE Transaction Situation: KORE Group Holdings is being sold for $9.25 per share to Searchlight Capital Partners and Abry Partners, prompting shareholders to consider the implications of this transaction on their rights and available legal options.
- Centessa Transaction Analysis: Centessa Pharmaceuticals is being sold for $38.00 per share in cash, plus a non-transferable right entitling holders to receive up to $9.00 upon achieving certain milestones, urging shareholders to understand their legal rights and options.
See More
Monteverde Law Firm Investigates Multiple Biotech Companies
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Kezar Life Sciences, Inc. and Aurinia Pharmaceuticals Inc., with Kezar shareholders expected to receive $6.955 per share in cash and a non-transferable contingent value right, aiming to protect shareholder interests and ensure transaction fairness.
- Centessa Transaction Details: In the deal between Centessa Pharmaceuticals plc and Eli Lilly, Centessa shareholders are anticipated to receive $38.00 per share in cash along with a contingent value right that could yield up to $9.00 based on certain milestones, demonstrating the company's commitment to shareholder value.
- Talkspace Shareholder Rights: In the transaction involving Talkspace, Inc. and Universal Health Services, Inc., Talkspace shareholders will receive $5.25 per share in cash, indicating the deal aims to provide direct cash returns to shareholders and enhance their confidence.
- Warner Bros. Transaction Progress: Warner Bros. Discovery, Inc. is set to receive $31.00 per share in cash and additional compensation based on elapsed time in its deal with Paramount Skydance Corporation, with a shareholder vote scheduled for April 23, 2026, reflecting the company's transparency and the importance of shareholder engagement in mergers.
See More
